SEC Form 4 · accession 0000899243-17-001440
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine A. Carberry
Officer — Chief Operating Officer
Period of report
Jan 17, 2017
Accepted (ET)
Jan 18, 2017 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock (Restricted)F1 | Jan 17, 2017 | A | 85,000 | $0.00 | A | 85,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $6.02 | Jan 17, 2017 | A | 170,000 | A | — | Jan 17, 2027 | Common Stock | 170,000 | 170,000 | D |
Explanation of responses
- F1The 85,000 shares are restricted common stock, which will vest over three years with the first one-third vesting on January 17, 2018, and the remaining shares vesting in equal quarterly installments through the third anniversary of the grant date on January 17, 2020.
- F2The options vest according to the following schedule: the first one-third of the 170,000 options will vest on January 17, 2018, and the remaining options shall vest in equal quarterly installments through the third anniversary of the grant date on January 17, 2020.